Company Performance: LIDDS.ST's financial health and growth prospects greatly influence its stock price. Positive earnings reports, successful clinical trials, and promising pipeline developments can boost investor confidence.

Market Sentiment: General market trends and investor psychology play a significant role. Positive overall market conditions and optimism towards pharmaceutical stocks can drive LIDDS.ST's price upward.

Regulatory Approvals: Approval of LIDDS's pharmaceutical products by regulatory bodies like the EMA or FDA is a crucial catalyst. Approvals significantly de-risk the investment and validate the technology.

Competition: The competitive landscape within the drug delivery and oncology sectors impacts LIDDS.ST's valuation. The presence of competing technologies or successful products can negatively affect the stock.

Industry Trends: Overall trends in drug development, personalized medicine, and targeted therapies influence the demand for LIDDS.ST's technology. Rising interest in these areas can increase investor appetite.

Management Team: The experience and reputation of LIDDS.ST's leadership team affect investor trust. Competent management inspires confidence and positive sentiment.

Partnerships and Collaborations: Collaborations with larger pharmaceutical companies or research institutions can validate LIDDS.ST's technology and provide access to resources, impacting the stock price.

Clinical Trial Results: Results from clinical trials of LIDDS's drug candidates are major drivers of stock price movements. Positive trial data indicating efficacy and safety can lead to significant gains.

Economic Factors: Broader economic conditions, such as interest rates and inflation, can affect investor appetite for riskier assets like pharmaceutical stocks, indirectly impacting LIDDS.ST.

Investor Relations: Effective communication with investors and transparency about the company's progress are essential for maintaining confidence and positively influencing the stock price.